- Home
- ACIU vs POLE Comparison
ACIU vs POLE Comparison
Compare ACIU & POLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- POLE
- Stock Information
- Founded
- ACIU 2003
- POLE 2024
- Country
- ACIU Switzerland
- POLE United States
- Employees
- ACIU N/A
- POLE N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- POLE
- Sector
- ACIU Health Care
- POLE
- Exchange
- ACIU Nasdaq
- POLE NYSE
- Market Cap
- ACIU 270.1M
- POLE 296.0M
- IPO Year
- ACIU 2016
- POLE 2024
- Fundamental
- Price
- ACIU $2.65
- POLE $10.08
- Analyst Decision
- ACIU Strong Buy
- POLE
- Analyst Count
- ACIU 2
- POLE 0
- Target Price
- ACIU $12.00
- POLE N/A
- AVG Volume (30 Days)
- ACIU 203.0K
- POLE 3.6K
- Earning Date
- ACIU 03-13-2025
- POLE 01-01-0001
- Dividend Yield
- ACIU N/A
- POLE N/A
- EPS Growth
- ACIU N/A
- POLE N/A
- EPS
- ACIU N/A
- POLE N/A
- Revenue
- ACIU $48,505,404.00
- POLE N/A
- Revenue This Year
- ACIU $86.78
- POLE N/A
- Revenue Next Year
- ACIU $118.22
- POLE N/A
- P/E Ratio
- ACIU N/A
- POLE N/A
- Revenue Growth
- ACIU 4097200.00
- POLE N/A
- 52 Week Low
- ACIU $2.25
- POLE $9.94
- 52 Week High
- ACIU $4.98
- POLE $11.05
- Technical
- Relative Strength Index (RSI)
- ACIU 47.51
- POLE N/A
- Support Level
- ACIU $2.39
- POLE N/A
- Resistance Level
- ACIU $2.74
- POLE N/A
- Average True Range (ATR)
- ACIU 0.14
- POLE 0.00
- MACD
- ACIU 0.01
- POLE 0.00
- Stochastic Oscillator
- ACIU 56.52
- POLE 0.00
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About POLE ANDRETTI ACQUISITION CORP. II
Andretti Acquisition Corp II is a blank check company.